Level Four Advisory Services, LLC Intra Cellular Therapies, Inc. Transaction History

Level Four Advisory Services, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$64.37 - $75.65 $5,149 - $6,052	80 Added 2.67%	3,076 $212,000
Q4 2023 Feb 08, 2024	BUY	$46.37 - $73.65 $138,924 - $220,655	2,996 New	2,996 $214,000
Q2 2023 Jul 10, 2023	BUY	$54.67 - $66.44 $409,095 - $497,170	7,483 New	7,483 $473,000
Q4 2022 Feb 13, 2023	SELL	$44.07 - $54.45 $17,539 - $21,671	-398 Reduced 5.34%	7,052 $373,000
Q3 2022 Nov 07, 2022	SELL	$42.7 - $59.99 $297,832 - $418,430	-6,975 Reduced 48.35%	7,450 $347,000
Q2 2022 Aug 08, 2022	SELL	$43.0 - $65.64 $10,191 - $15,556	-237 Reduced 1.62%	14,425 $823,000
Q1 2022 May 10, 2022	BUY	$38.74 - $62.09 $568,005 - $910,363	14,662 New	14,662 $897,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.92B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Level Four Advisory Services, LLC with notifications on news.